Perfusion Imaging Market By 2024 to 2034: Advances in Imaging Hardware and Software from Sanket Badgujar's blog

The global perfusion imaging market is poised for substantial growth, with projections indicating a revenue surge to nearly USD 2,421.4 million by 2024. According to Future Market Insights (FMI), this upward trajectory is driven by the escalating demand for perfusion imaging equipment in healthcare facilities worldwide. FMI forecasts a steady Compound Annual Growth Rate (CAGR) of 3.4% for the perfusion imaging market from 2024 to 2034, culminating in an estimated net worth of nearly USD 3,382.8 million by 2034.

The burgeoning prevalence of myocardial infarction and ischemic heart disease underscores the critical importance of perfusion imaging in modern medicine. With cardiovascular diseases remaining a leading cause of mortality globally, there is an increasing emphasis on early detection and precise diagnostic tools. Perfusion imaging emerges as a pivotal diagnostic modality, offering clinicians valuable insights into myocardial blood flow and tissue viability.

Get Access to Sample Now: https://www.futuremarketinsights.com/reports/sample/rep-gb-9650

Furthermore, the growing preference for non-invasive diagnostic techniques is propelling the adoption of perfusion imaging across a spectrum of healthcare settings, including hospitals and clinics. Patients and healthcare providers alike are increasingly gravitating towards diagnostic solutions that minimize invasiveness while delivering accurate and actionable results.

The evolution of perfusion imaging technologies promises to revolutionize patient care, enabling healthcare professionals to make informed decisions swiftly and effectively. With advancements in imaging modalities and data analytics, perfusion imaging is poised to play an even more integral role in the diagnosis and management of cardiovascular diseases and other medical conditions.

As the global healthcare landscape continues to evolve, the perfusion imaging market stands at the forefront of innovation, driving improvements in diagnostic accuracy, patient outcomes, and overall healthcare delivery.

Key Takeaways from the Perfusion Imaging Market Study Report:

• The United States is witnessing a comparatively slow growth rate of 1.9% due to market saturation that is estimated to continue till 2034.
• Germany holds a significant share of the European diagnostic imaging market and is penned in to advance at 2.5% CAGR between 2024 and 2034.
• In Asia, India is currently creating a noticeable demand for perfusion scanners resulting in an estimated CAGR of 5.0% for the projected years.
• Thailand is another steadily growing market with an estimated CAGR of 3.5% from 2024 to 2034.

Competitive Landscape for the Perfusion Imaging Market Players:

The overall market is diversifying slowly with government support in emerging economies to their regional players. Better image resolution, speed, and accuracy of perfusion imaging solutions from leading market players are becoming more useful for diagnosing and tracking a wide range of medical disorders. Meanwhile, emerging market players are resorting to collaborations and mergers with big players to gain technical advantage in their respective regions.

“Prevalence of neurological and cardiovascular illnesses, particularly in the United States and Europe, has resulted in a highly developed healthcare system for adoption of perfusion scanning equipment and technologies. However, swift developing economies such as India, China, and South Korea are strengthening their healthcare infrastructure favoring the regional diagnostic imaging market in Asia,” – says a lead analyst at FMI.

Recent Developments by the Perfusion Imaging Industry Participants:

• In November 2023, Brainomix, based in the United States, announced the release of its entire suite of FDA-cleared components in its Brainomix 360 platform which is an integrated stroke imaging solution. The firm had previously announced an FDA-cleared e-ASPECTS component which presents a platform designed to help doctors make imaging-based treatment decisions at all stages of the stroke pathway. The Brainomix 360 e-ASPECTS smartphone app is also an FDA-cleared decision support tool for evaluating stroke symptoms on plain CT brain imaging.
• In March 2024, Lantheus Holdings Incorporated, based in the United States, announced that the Food and Drug Administration (FDA) approved its supplemental new drug application (sNDA) for DEFINITY® (Perflutren Lipid Microsphere). It can be used as an ultrasound-enhancing agent for use in pediatric patients with suboptimal echocardiograms. This clearance marks a significant advancement in pediatric medicine and DEFINITY boasts of being the most widely used, well-researched, and reliable diagnostic ultrasound-enhancing agent in the country.

Key Players Profiled in the Perfusion Imaging Market Report:

• GE Healthcare
• Toshiba Medical System.
• Positron
• Aetna Inc.
• NeuSoft
• Bracco
• Cigna
• Kmhlabs
• Perimed AB.
• Siemens Health
• Philips Healthcare
• Lantheus Medical Cardiac Imaging Solutions Inc.

Key Segments Covered by Perfusion Imaging Industry Survey Report:

By Modality Type:

• Single Photon Emission Computed Tomography (SPECT)
• Positron Emission Tomography (PET)
• Magnetic Resonance Imaging (MRI)
• Computed tomography (CT)
• Doppler echocardiography

By Application:

• Coronary artery disease (CAD)
• Myocardial infarction (MI)
• Cardiomyopathy
• Epilepsy
• Dementia
• Transplant evaluation
• Brain Trauma
• Pulmonary embolism (PE)
• Osteonecrosis
• Other Applications

By End User Verticals:

• Hospitals
• Ambulatory Surgery Center
• Diagnostic Imaging Centers
• Other End Users

By Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia and Pacific
• Middle East and Africa (MEA)